Pharma M&A versus alliances and its underlying value drivers - Are M&A or alliances the right therapy for an ailing pharmaceutical industry?- A capital market perspective

From a capital market perspective, the author analyzes Merger and Acquisitions transactions (M&A) and in-licensings in the pharmaceutical industry between 1998 and 2012. Utilizing the event study methodology, the volume shows that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. But what are the underlying value drivers which make a deal a success or a failure story? The author derives significant innovative determinants of success for both strategies.

List of contents

Contents: The Pharmaceutical Industry and its Paradigm Shift - The Pharmaceutical Industry and Mergers & Acquisitions - Value Creation in Pharmaceutical M&A and its underlying Value Drivers - The Pharmaceutical Industry and Alliances - Value Creation in Pharmaceutical In-licensings and its underlying Value Drivers - M&A versus In-licensing.

About the author

Heiko Schön studied international business administration at Wiesbaden Business School. He was scholar of the German National Merit Foundation (sdw), he owns an Executive MBA from the University of Münster and earned his PhD at the University of Darmstadt. He brings in 10 years of experience in the pharmaceutical and chemical industry.

Product details

• Authors: Heiko Schön
• Assisted by: Dirk Schiereck (Editor)
• Publisher: Peter Lang
• Languages: English
• Product format: Hardback
• Released: 31.05.2016
• EAN: 9783631663813
• ISBN: 978-3-631-66381-3
• No. of pages: 201
• Dimensions: 148 mm x 16 mm x 210 mm
• Weight: 360 g
• Series: Corporate Finance and Governance; Corporate Finance and Governance
• Subjects: Natural sciences, medicine, IT, technology > Medicine; Social sciences, law, business > Business > Business administration